Across TCGA pan-cancer cohorts, YAP1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated YAP1 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher YAP1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated YAP1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
KICH, BLCA, and LUSC are the cancer types where YAP1 Mutation most reproducibly stratifies survival.